Natasha B. Leighl mainly investigates Internal medicine, Lung cancer, Oncology, Surgery and Cancer. Her study looks at the relationship between Internal medicine and topics such as Gastroenterology, which overlap with Mesothelioma. Natasha B. Leighl has included themes like Survival rate, Carcinoma and Chemotherapy in her Lung cancer study.
Her research in Oncology intersects with topics in Docetaxel, KRAS, Epidermal growth factor receptor and Bioinformatics. The study of Surgery is intertwined with the study of Placebo in a number of ways. Her Cancer research incorporates themes from Anxiety, Prospective cohort study, Pathology and Combination chemotherapy.
Natasha B. Leighl mostly deals with Internal medicine, Oncology, Lung cancer, Cancer and Surgery. In the field of Internal medicine, her study on Chemotherapy, non-small cell lung cancer, Clinical trial and Randomized controlled trial overlaps with subjects such as In patient. Her Oncology study incorporates themes from Stage, Cisplatin, Docetaxel and Pathology.
Her research investigates the connection between Lung cancer and topics such as Cancer research that intersect with problems in Lung. Cancer is closely attributed to Family medicine in her study. Her studies in Surgery integrate themes in fields like Gastroenterology and Hazard ratio.
Natasha B. Leighl focuses on Internal medicine, Oncology, Lung cancer, Cancer research and Cancer. She performs multidisciplinary study in Internal medicine and In patient in her work. Natasha B. Leighl combines subjects such as Hazard ratio, Phases of clinical research, Lung, Durvalumab and Stage with her study of Oncology.
Her work carried out in the field of Lung cancer brings together such families of science as Liquid biopsy, Quality of life and Epidermal growth factor receptor. When carried out as part of a general Cancer research project, her work on Immune checkpoint is frequently linked to work in Focus group and Qualitative property, therefore connecting diverse disciplines of study. The concepts of her Clinical trial study are interwoven with issues in Adverse effect and Randomized controlled trial.
Internal medicine, Lung cancer, Oncology, Cancer and Clinical trial are her primary areas of study. Her Internal medicine and Adverse effect, Randomized controlled trial, Incidence, Nivolumab and Confidence interval investigations all form part of her Internal medicine research activities. Natasha B. Leighl interconnects Combination therapy, Chemotherapy, Epidermal growth factor receptor and Cohort in the investigation of issues within Lung cancer.
Her Oncology research incorporates elements of Stage iv, Pembrolizumab, Immunotherapy and Hazard ratio. Her work in the fields of Cancer, such as Immune checkpoint, intersects with other areas such as Focus group, Qualitative property and Pandemic. Her Clinical trial research is multidisciplinary, relying on both Intensive care medicine, Placebo, Carcinoma, Erlotinib and Durvalumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl.
The New England Journal of Medicine (2015)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins.
Journal of Clinical Oncology (2018)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Martin Reck;Joachim von Pawel;Petr Zatloukal;Rodryg Ramlau.
Journal of Clinical Oncology (2009)
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon.
The Lancet (2014)
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck;J Von Pawel;P. Zatloukal;R. Ramlau.
Annals of Oncology (2010)
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith;Kari Bohlke;Gary H. Lyman;Kenneth R. Carson.
Journal of Clinical Oncology (2015)
Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis
Rebecca G. Hagerty;Phyllis N. Butow;Peter M. Ellis;Elizabeth A. Lobb.
Journal of Clinical Oncology (2005)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp.
Journal of Clinical Oncology (2017)
Cancer patient preferences for communication of prognosis in the metastatic setting.
Rebecca G. Hagerty;Phyllis N. Butow;Peter A. Ellis;Elizabeth A. Lobb.
Journal of Clinical Oncology (2004)
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen;Rajat Singhania;Gordon Fehringer;Ankur Chakravarthy.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: